Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: $APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apyx Medical Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apyx Medical Corporation's position in the market.
Rhea-AI Summary
Apyx Medical (NASDAQ:APYX) will release its first quarter fiscal year 2024 financial results on May 9, 2024. A conference call will be held to discuss the results and host a question and answer session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
News
Rhea-AI Summary
Apyx Medical announces the Renuvion Users' Summit in Las Vegas, showcasing innovative research on Renuvion technology for cosmetic and plastic surgery. The summit features key opinion leaders presenting new data on body contouring, fat transfer, and safety of Renuvion, aiming to enhance patient outcomes and provide top-notch care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
-
Rhea-AI Summary
Apyx Medical (APYX) reports a 15% increase in Advanced Energy sales year-over-year in the fourth quarter, with total revenue reaching $14.7 million. The company also introduces financial expectations for 2024, with a focus on managing resources efficiently and strategic investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.65%
Tags
Rhea-AI Summary
Apyx Medical Corporation (APYX) to release financial results for Q4 and FY 2023 on March 21st, with a conference call to discuss the outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation announces that its Renuvion technology will be featured in educational sessions at the American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting. Dr. Michael Kluska will present results of a clinical study showing fewer adverse events with Renuvion compared to a competing technology in liposuction and body contouring procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. The analysis of data from 483 patients found no new or increased risks for any area of the body compared to the use of liposuction alone. The study demonstrated Renuvion's impressive safety when used after liposuction, which led to securing FDA 510(k) clearance for the use of Renuvion APR Handpiece. The authors concluded that the use of Renuvion following liposuction for any particular area of the body demonstrated no new or increased risks compared to published data for patients having liposuction performed alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023. Total revenue for Q4 2023 was approximately $14.2 to $14.6 million, representing 13% to 16% year-over-year growth. Full year 2023 revenue was approximately $51.9 to $52.3 million, showing 17% to 18% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation (APYX) announced a new $45 million credit agreement with Perceptive Credit Holdings IV, LP, providing access to additional capital at more attractive terms. The facility includes senior, secured term loans, with an initial loan of $37.5 million fully drawn at closing. The agreement matures on November 8, 2028, with an initial loan of $37.5 million and a delayed draw loan of $7.5 million. The loans bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The Perceptive Credit Agreement provides for 48 months of interest-only payments, with subsequent monthly payments of 3.0% of the outstanding balance. The obligations under the facility are secured by first priority liens on substantially all of the Company's assets. In connection with the initial loan, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported a 39% year-over-year increase in Q3 Advanced Energy sales, reaching $9.8 million. The Company also announced a new credit agreement and updated its financial expectations for the full year. The third quarter results showed a 31% year-over-year increase in total revenue to $12.0 million, with a net loss of $4.6 million. The updated guidance for 2023 includes a total revenue range of $53.0 million to $54.0 million, representing a 19% to 21% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in upcoming investor conferences, including the Stephens Annual Investment Conference, Craig-Hallum 14th Annual Alpha Select Conference, and Piper Sandler 35th Annual Healthcare Conference. Management will engage in fireside chats and 1x1 meetings, with audio webcasts available for replay on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Apyx Medical Corporation
Nasdaq:APYX
APYX Rankings
APYX Stock Data
48.85M
24.98M
17.92%
48.15%
2.04%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
CLEARWATER
About APYX
apyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed